Characterizing NSCLC tumor microenvironment using the integrated MultiOmyx-RNAscope

Sponsored by:

Areas covered:

• Co-detection of RNA and protein provides critical information such as the source of secreted proteins (e.g. cytokines) or cell type specific transcript levels.
• The novel integrated RNAscope-MultiOmyx IF assay is a robust and sensitive platform for simultaneous detection of multiple RNA and protein biomarkers.
• This integrated approach is shown to spatially correlate the distribution of cytokine RNA expression in immune cell subsets within the tumor microenvironment of NSCLC samples.

Date: 26 May 2021 (Wednesday)
Time: New York – 11:00 | London – 16:00 | Paris – 17:00 | Singapore – 23:00 |Tokyo – 00: 00 (27 May) |Sydney – 01:00 (27 May)
Duration: 45 minutes
Event structure: 35-minute presentation + 10-minute Q&A
Registration fee: Complimentary access
Webinar on-demand: Available to view until midnight 12 June 2021 (registration is required)

Dr. Todorov is a Lead Scientist within the Multiplexing team in the Pharma Services division at NeoGenomics. Her work focuses on developing assays to improve biomarker spatial analysis using the MultiOmyx multiplex-immunofluorescence (IF) platform. She earned her Ph.D. in developmental biology at the University of California, Irvine (UCI) followed by a postdoctoral fellowship studying tissue regeneration and stem cells at the University of California, San Francisco (UCSF). Prior to joining NeoGenomics, Courtney was a Senior Scientist at Advanced Cell Diagnostics where she developed novel RNAscope in-situ hybridization (ISH)-immunohistochemistry (IHC) based assays. Her combined experience has made her an expert in utilizing and developing histological IHC and ISH techniques to answer complex biological questions.